AstraZeneca inks $40 million AI partnership with insitro for liver and heart drugs
AstraZeneca has agreed to pay $40 million up front to AI biotech insitro to jointly discover treatments for severe liver disease and cardiomyopathies.
AstraZeneca announced a partnership with California-based AI biotech insitro, committing $40 million upfront and offering up to roughly $1.46 billion in development and commercial milestones, as well as royalty rights. The alliance will target metabolic dysfunction-associated steatohepatitis (MASH) and various cardiomyopathies, diseases that have lacked effective therapies. Insitro will use its Virtual Human platform, which integrates engineered cell models and machine-learning algorithms, to identify causal biology and move AstraZeneca-selected targets from discovery to candidate stage.
AstraZeneca will finance and conduct subsequent clinical trials. The agreement expands insitro's growing footprint in pharma, building on recent collaborations with Bristol Myers Squibb for ALS and with Eli Lilly on AI-driven small-molecule predictions. Executives highlighted that early AI-driven target identification can keep projects ahead of public disclosures and reduce laboratory guesswork.
Why it matters
The deal shows how AI is being integrated into drug discovery, potentially speeding up cures for hard-to-treat liver and heart diseases.
In this story
